Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12320484 | 0.77 | ADORA2A (0.41) | ADORA2AADORA1ADORA3ADORA2BECE1 | |
| SCHEMBL23701644 | 0.74 | ADORA2A (0.44) | ADORA2AADORA1ADORA3ADORA2BECE1 | |
| SCHEMBL12277712 | 0.70 | ADORA2A (0.43) | ADORA2AADORA1ADORA3ADORA2BECE1 | |
| SCHEMBL12277710 | 0.70 | ADORA2A (0.43) | ADORA2AADORA1ADORA3ADORA2BECE1 | |
| SCHEMBL3777152 | 0.69 | ECE1 (0.46) | ADORA2AADORA1ECE1PDPK1SMPD3 | |
| SCHEMBL24926667 | 0.68 | ADORA2A (0.47) | ADORA2AADORA1ADORA3ADORA2BECE1 | |
| SCHEMBL5785414 | 0.67 | PDPK1 (0.37) | ADORA2AADORA1ECE1PDPK1SMPD3 | |
| SCHEMBL6910076 | 0.67 | PLK1 (0.40) | ADORA2AADORA1ADORA3ADORA2BPDPK1 | |
| SCHEMBL20350315 | 0.67 | — | — | |
| SCHEMBL18415036 | 0.66 | TYK2 (0.39) | ADORA2AADORA1ADORA3ADORA2BPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-05-07 | — | — | US | disclosed |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8445503-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | ADORA2A 3335/4885ADORA1 1980/4885ADORA3 1659/4885 |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | ADORA2A 3299/4885ADORA1 1901/4885ADORA3 1601/4885 |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | ADORA2A 3299/4885ADORA1 1901/4885ADORA3 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.